Concerns arise from the decreasing ROCE trend and stagnant sales despite reinvestment for growth. These trends may have led to the stock's 70% drop in the last three years. The company's current trends do not align with typical multi-baggers, suggesting investors may need to look elsewhere.

Shareholders hold onto stock despite poor performance and high P/E ratio, banking on predicted growth. The company's future earnings and share price stability remain uncertain.

Despite Shanghai Titan Scientific's recent stock decline and low ROE, the company shows signs of efficient management with promising future earnings growth. Its fundamentals remain solid for long-term investment.